IP Library Granted Patent US 7,135,463
Granted Patent B2
US 7,135,463 · App. 10/759,328 · Granted Nov 14, 2006

RHoB as a suppressor of cancer cell growth, cell transformation, and metastasis

Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,463
App. No.
10/759,328
Granted
Nov 14, 2006
Kind
B2
Abstract

The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous cell decreases phosphorylation of Erk and Akt proteins inhibiting the PI3-kinase/Akt cell survival pathway and promoting apoptotic cell death. In one aspect, the compositions and methods of the present invention are used to inhibit the malignant transformation of cells by the oncogenes H-Ras, N-Ras, K-Ras, EGFR, or ErbB2, or to inhibit the growth of cancer cells transformed by such oncogenes. The compositions and methods of the present invention may be used to inhibit cancer cell growth, inhibit malignant cell transformation, and modulate oncogenic signaling in vivo or in vitro.

Claims (16)

1. A method for inhibiting the growth of a tumor cells in a mammal wherein the tumor cells are transformed by at least one oncogene selected from the group consisting of H-Ras, N-Ras, K-Ras, EGFR, and ErbB2, comprising directly administering an effective amount of a nucleic acid sequence encoding a wild-type RhoB protein to the tumor cells, wherein the nucleic acid sequence is expressed in the tumor cells.

2. The method of claim 1 , wherein said method further comprises administering an additional anti-cancer agent to the tumor cells.

3. The method of claim 2 , wherein the additional anti-cancer agent comprises a cytotoxic agent or an anti-signaling agent.

4. The method of claim 2 , wherein the RhoB protein sensitizes the tumor cells to the anti-cancer agent.

5. The method of claim 1 , wherein the nucleic acid sequence is associated with a pharmaceutically acceptable carner.

6. The method of claim 1 , wherein the tumor cells are cells of a solid tumor mass.

7. The method of claim 1 , wherein the tumor cells are not v-src trnsformed cells.

8. The method of claim 1 , wherein the tumor cells are cells of a type selected from the group consisting of pancreatic cancer, prostate cancer, breast cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, and melanoma cancer.

9. The method of claim 1 , wherein the tumor cells are lung cancer cells.

10. The method of claim 1 , wherein the mammal is human.

11. The method of claim 1 , wherein said administering comprises administering a viral vector containing the nucleic acid sequence to the tumor cells.

12. The method of claim 11 , wherein the viral vector is adenovirus.

13. The method of claim 11 , wherein the viral vector is adenovirus and the tumor cells are lung cancer cells.

14. The method of claim 1 , wherein the tumor cells are liver cancer cells.

15. The method of claim 1 , wherein the tumor cells are head and neck cancer cells.

16. The method of claim 1 , wherein the tumor cells are melanoma cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 4, 2011
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026072/0934 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2004
From: SEBTI, SAID M.
To: SOUTH FLORIDA, UNIVERSITY OF
Reel/Frame 014613/0180 →
Continuity (4)
Continuation In Part 1004950200
Provisional Application 6050621900 · Sep 25, 2003
Provisional Application 6021204900 · Jun 16, 2000
Related Publication 20040171547A1 · Sep 2, 2004